{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:45:24Z","timestamp":1772714724144,"version":"3.50.1"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T00:00:00Z","timestamp":1408492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cytokine-targeted therapy has generated a paradigm shift in the treatment of several immune-mediated diseases. Interleukin-6 (IL-6), which was initially identified as B-cell stimulatory factor 2, is a prototypical cytokine with wide-ranging biological effects on immune cells such as B and T cells, on hepatocytes, hematopoietic cells, vascular endothelial cells and on many others. IL-6 is thus crucially involved in the regulation of immune responses, hematopoiesis and inflammation. When infections and tissue injuries occur, IL-6 is promptly synthesized and performs a protective role in host defense against such stresses and traumas. However, excessive production of IL-6 during this emergent process induces potentially fatal complications, including systemic inflammatory response syndrome (SIRS), and dysregulated, persistently high expression of IL-6 causes the onset or development of various chronic immune-mediated disorders. For these reasons, IL-6 blockade was expected to become a novel therapeutic strategy for various diseases characterized by IL-6 overproduction. Indeed, worldwide clinical trials of tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody, have successfully proved its outstanding efficacy against rheumatoid arthritis, juvenile idiopathic arthritis and Castleman disease, leading to the approval of tocilizumab for the treatment of these diseases. Moreover, various reports regarding off-label use of tocilizumab strongly suggest that it will be widely applicable for acute, severe complications such as SIRS and cytokine-release syndrome and other refractory chronic immune-mediated diseases.<\/jats:p>","DOI":"10.1093\/intimm\/dxu081","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T01:12:47Z","timestamp":1408583567000},"page":"21-29","source":"Crossref","is-referenced-by-count":137,"title":["Therapeutic uses of anti-interleukin-6 receptor antibody"],"prefix":"10.1093","volume":"27","author":[{"given":"Sujin","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine 1 , 2-2 Yamada-oka, Suita City, Osaka 565-0871 , Japan"},{"name":"Department of Immunopathology 2 , World Premier International Immunology Frontier Research Center, Osaka University, 3-1 Yamada-oka, Suita City, Osaka 565-0871, Japan"}]},{"given":"Toshio","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine 1 , 2-2 Yamada-oka, Suita City, Osaka 565-0871 , Japan"},{"name":"Department of Immunopathology 2 , World Premier International Immunology Frontier Research Center, Osaka University, 3-1 Yamada-oka, Suita City, Osaka 565-0871, Japan"}]},{"given":"Tadamitsu","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Laboratory of Immune Regulation, World Premier International Immunology Frontier Research Center, Osaka University 3 , 3-1 Yamada-oka, Suita City, Osaka 565-0871 , Japan"}]}],"member":"286","published-online":{"date-parts":[[2014,8,20]]},"reference":[{"key":"2022072021385469600_CIT0001","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0092-8674(89)90121-9","article-title":"Pleiotropy and redundancy: T cell-derived lymphokines in the immune response","volume":"57","author":"Paul","year":"1989","journal-title":"Cell"},{"key":"2022072021385469600_CIT0002","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.iy.06.040188.002413","article-title":"Molecular regulation of B lymphocyte response","volume":"6","author":"Kishimoto","year":"1988","journal-title":"Annu. Rev. Immunol"},{"key":"2022072021385469600_CIT0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"2022072021385469600_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The biology of interleukin-6","volume":"74","author":"Kishimoto","year":"1989","journal-title":"Blood"},{"key":"2022072021385469600_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60532-5","article-title":"Interleukin-6 in biology and medicine","volume":"54","author":"Akira","year":"1993","journal-title":"Adv. Immunol"},{"key":"2022072021385469600_CIT0006","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1126\/science.1411569","article-title":"Interleukin-6 and its receptor: a paradigm for cytokines","volume":"258","author":"Kishimoto","year":"1992","journal-title":"Science"},{"key":"2022072021385469600_CIT0007","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/368339a0","article-title":"Impaired immune and acute-phase responses in interleukin-6-deficient mice","volume":"368","author":"Kopf","year":"1994","journal-title":"Nature"},{"key":"2022072021385469600_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: from basic science to medicine\u201440 years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu. Rev. Immunol"},{"key":"2022072021385469600_CIT0009","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-pharmtox-010611-134715","article-title":"Therapeutic targeting of the interleukin-6 receptor","volume":"52","author":"Tanaka","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol"},{"key":"2022072021385469600_CIT0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.smim.2014.01.009","article-title":"A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy","volume":"26","author":"Tanaka","year":"2014","journal-title":"Semin. Immunol"},{"key":"2022072021385469600_CIT0011","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1073\/pnas.84.20.7251","article-title":"Interferon beta 2\/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells","volume":"84","author":"Gauldie","year":"1987","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022072021385469600_CIT0012","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0014-5793(87)80344-7","article-title":"Recombinant human B cell stimulatory factor 2 (BSF-2\/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells","volume":"221","author":"Andus","year":"1987","journal-title":"FEBS Lett"},{"key":"2022072021385469600_CIT0013","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"2022072021385469600_CIT0014","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1073\/pnas.89.1.232","article-title":"Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice","volume":"89","author":"Suematsu","year":"1992","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022072021385469600_CIT0015","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol"},{"key":"2022072021385469600_CIT0016","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.20120994","article-title":"The origins, function, and regulation of T follicular helper cells","volume":"209","author":"Ma","year":"2012","journal-title":"J. Exp. Med"},{"key":"2022072021385469600_CIT0017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1074-7613(00)80334-9","article-title":"Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment","volume":"6","author":"Romano","year":"1997","journal-title":"Immunity"},{"key":"2022072021385469600_CIT0018","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jbmr.5650110113","article-title":"Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation","volume":"11","author":"Kotake","year":"1996","journal-title":"J. Bone Miner. Res"},{"key":"2022072021385469600_CIT0019","first-page":"22","article-title":"Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis","volume":"19","author":"Dasgupta","year":"1992","journal-title":"J. Rheumatol"},{"key":"2022072021385469600_CIT0020","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","article-title":"Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2022072021385469600_CIT0021","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0167-5699(90)90139-Z","article-title":"Haemopoietic receptors and helical cytokines","volume":"11","author":"Bazan","year":"1990","journal-title":"Immunol. Today"},{"key":"2022072021385469600_CIT0022","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.3136546","article-title":"Cloning and expression of the human interleukin-6 (BSF-2\/IFN beta 2) receptor","volume":"241","author":"Yamasaki","year":"1988","journal-title":"Science"},{"key":"2022072021385469600_CIT0023","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","article-title":"Molecular cloning and expression of an IL-6 signal transducer, gp130","volume":"63","author":"Hibi","year":"1990","journal-title":"Cell"},{"key":"2022072021385469600_CIT0024","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J. Clin. Invest"},{"key":"2022072021385469600_CIT0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(94)90333-6","article-title":"Cytokine signal transduction","volume":"76","author":"Kishimoto","year":"1994","journal-title":"Cell"},{"key":"2022072021385469600_CIT0026","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.V86.4.1243.bloodjournal8641243","article-title":"Interleukin-6 family of cytokines and gp130","volume":"86","author":"Kishimoto","year":"1995","journal-title":"Blood"},{"key":"2022072021385469600_CIT0027","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1146\/annurev.immunol.15.1.797","article-title":"Gp130 and the interleukin-6 family of cytokines","volume":"15","author":"Taga","year":"1997","journal-title":"Annu. Rev. Immunol"},{"key":"2022072021385469600_CIT0028","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/43219","article-title":"Structure and function of a new STAT-induced STAT inhibitor","volume":"387","author":"Naka","year":"1997","journal-title":"Nature"},{"key":"2022072021385469600_CIT0029","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1126\/science.278.5344.1803","article-title":"Specific inhibition of Stat3 signal transduction by PIAS3","volume":"278","author":"Chung","year":"1997","journal-title":"Science"},{"key":"2022072021385469600_CIT0030","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1084\/jem.20090560","article-title":"Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses","volume":"206","author":"Kimura","year":"2009","journal-title":"J. Exp. Med"},{"key":"2022072021385469600_CIT0031","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/intimm\/dxt011","article-title":"The roles of aryl hydrocarbon receptor in immune responses","volume":"25","author":"Nguyen","year":"2013","journal-title":"Int. Immunol"},{"key":"2022072021385469600_CIT0032","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature06881","article-title":"The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins","volume":"453","author":"Veldhoen","year":"2008","journal-title":"Nature"},{"key":"2022072021385469600_CIT0033","doi-asserted-by":"crossref","first-page":"14222","DOI":"10.1073\/pnas.1111786108","article-title":"Aryl hydrocarbon receptor deficiency in T cells suppresses the development of collagen-induced arthritis","volume":"108","author":"Nakahama","year":"2011","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022072021385469600_CIT0034","doi-asserted-by":"crossref","first-page":"19961","DOI":"10.1073\/pnas.1014465107","article-title":"Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism","volume":"107","author":"Nguyen","year":"2010","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022072021385469600_CIT0035","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ni1584","article-title":"Post-transcriptional control of cytokine production","volume":"9","author":"Anderson","year":"2008","journal-title":"Nat. Immunol"},{"key":"2022072021385469600_CIT0036","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/nature07924","article-title":"Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay","volume":"458","author":"Matsushita","year":"2009","journal-title":"Nature"},{"key":"2022072021385469600_CIT0037","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1073\/pnas.1307419110","article-title":"Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo","volume":"110","author":"Masuda","year":"2013","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022072021385469600_CIT0038","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/ni.2137","article-title":"The I\u03baB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1","volume":"12","author":"Iwasaki","year":"2011","journal-title":"Nat. Immunol"},{"key":"2022072021385469600_CIT0039","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol. Res"},{"key":"2022072021385469600_CIT0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.84.1.228","article-title":"Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production","volume":"84","author":"Hirano","year":"1987","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022072021385469600_CIT0041","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"key":"2022072021385469600_CIT0042","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"2022072021385469600_CIT0043","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V95.1.56.001k13_56_61","article-title":"Improvement in Castleman\u2019s disease by humanized anti-interleukin-6 receptor antibody therapy","volume":"95","author":"Nishimoto","year":"2000","journal-title":"Blood"},{"key":"2022072021385469600_CIT0044","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"2022072021385469600_CIT0045","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2022072021385469600_CIT0046","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022072021385469600_CIT0047","first-page":"141","article-title":"Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors","volume":"8","author":"Tanaka","year":"2014","journal-title":"Biologics"},{"key":"2022072021385469600_CIT0048","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","article-title":"Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)","volume":"72","author":"Dougados","year":"2013","journal-title":"Ann. Rheum. Dis"},{"key":"2022072021385469600_CIT0049","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s10067-013-2309-0","article-title":"Reduction of plasma IL-6 but not TNF-\u03b1 by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression","volume":"32","author":"Nishina","year":"2013","journal-title":"Clin. Rheumatol"},{"key":"2022072021385469600_CIT0050","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"key":"2022072021385469600_CIT0051","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5772\/20245","article-title":"Tocilizumab for the treatment of AA amyloidosis","volume-title":"Amyloidosis\u2014An Insight to Disease of Systems and Novel Therapies","author":"Tanaka","year":"2011"},{"key":"2022072021385469600_CIT0052","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar4323","article-title":"Comparative evaluation of the effects of treatment with tocilizumab and TNF-\u03b1 inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res. Ther"},{"key":"2022072021385469600_CIT0053","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Brief report: inhibition of interleukin-6 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022072021385469600_CIT0054","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/cei.12017","article-title":"Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients","volume":"171","author":"Pesce","year":"2013","journal-title":"Clin. Exp. Immunol"},{"key":"2022072021385469600_CIT0055","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/art.38246","article-title":"Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis","volume":"66","author":"Thiolat","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022072021385469600_CIT0056","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"2022072021385469600_CIT0057","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"2022072021385469600_CIT0058","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2022072021385469600_CIT0059","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod. Rheumatol"},{"key":"2022072021385469600_CIT0060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"key":"2022072021385469600_CIT0061","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"2022072021385469600_CIT0062","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nbt.1691","article-title":"Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization","volume":"28","author":"Igawa","year":"2010","journal-title":"Nat. Biotechnol"},{"key":"2022072021385469600_CIT0063","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"2022072021385469600_CIT0064","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med"},{"key":"2022072021385469600_CIT0065","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"}],"container-title":["International Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/intimm\/article-pdf\/27\/1\/21\/45033016\/intimm_27_1_21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/intimm\/article-pdf\/27\/1\/21\/45033016\/intimm_27_1_21.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T21:39:54Z","timestamp":1658353194000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/intimm\/article\/27\/1\/21\/2950830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,20]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,8,20]]},"published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/intimm\/dxu081","relation":{},"ISSN":["1460-2377","0953-8178"],"issn-type":[{"value":"1460-2377","type":"electronic"},{"value":"0953-8178","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,1]]},"published":{"date-parts":[[2014,8,20]]}}}